431 related articles for article (PubMed ID: 35306713)
1. SARS-CoV-2 vaccination-induced cutaneous vasculitis: Report of two new cases and literature review.
Abdelmaksoud A; Wollina U; Temiz SA; Hasan A
Dermatol Ther; 2022 Jun; 35(6):e15458. PubMed ID: 35306713
[TBL] [Abstract][Full Text] [Related]
2. A Case of Leukocytoclastic Vasculitis Following SARS-COV-2 Vaccination.
Ball-Burack MR; Kosowsky JM
J Emerg Med; 2022 Aug; 63(2):e62-e65. PubMed ID: 35690533
[TBL] [Abstract][Full Text] [Related]
3. SEVERE LEUKOCYTOCLASTIC VASCULITIS AFTER COVID-19 VACCINATION - CAUSE OR COINCIDENCE? CASE REPORT AND LITERATURE REVIEW.
Wollina U; Schönlebe J; Kodim A; Hansel G
Georgian Med News; 2022 Mar; (324):134-139. PubMed ID: 35417874
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination-a narrative review.
Wollina U; Chiriac A; Kocic H; Koch A; Brzezinski P
Wien Med Wochenschr; 2022 Mar; 172(3-4):63-69. PubMed ID: 34424434
[TBL] [Abstract][Full Text] [Related]
5. [Leukocytoclastic vasculitis and acute renal failure following inactivated SARS-CoV-2 vaccine].
Missoum S; Lahmar M; Khellaf G
Nephrol Ther; 2022 Jul; 18(4):287-290. PubMed ID: 35074300
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Small-vessel Vasculitis after ChAdOx1 COVID-19 Vaccination: A Report of Five Cases.
Uh JA; Lee SK; Kim JH; Lee JH; Kim MS; Lee UH
Int J Low Extrem Wounds; 2022 Jun; 21(2):193-196. PubMed ID: 35130095
[TBL] [Abstract][Full Text] [Related]
7. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination.
Larson V; Seidenberg R; Caplan A; Brinster NK; Meehan SA; Kim RH
J Cutan Pathol; 2022 Jan; 49(1):34-41. PubMed ID: 34292611
[TBL] [Abstract][Full Text] [Related]
8. New-onset systemic vasculitis following SARS-CoV-2 infection and vaccination: the trigger, phenotype, and outcome.
Mv P; Auanassova A; Yessirkepov M; Zimba O; Gasparyan AY; Kitas GD; Ahmed S
Clin Rheumatol; 2023 Oct; 42(10):2761-2775. PubMed ID: 37422611
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
10. A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports.
Sadat Larijani M; Doroud D; Banifazl M; Karami A; Bavand A; Ashrafian F; Ramezani A
Eur J Med Res; 2023 Nov; 28(1):542. PubMed ID: 38008729
[TBL] [Abstract][Full Text] [Related]
11. Leukocytoclastic vasculitis (cutaneous small-vessel vasculitis) after COVID-19 vaccination.
Fiorillo G; Pancetti S; Cortese A; Toso F; Manara S; Costanzo A; Borroni RG
J Autoimmun; 2022 Feb; 127():102783. PubMed ID: 34973526
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous vasculitis due to COVID-19 vaccination.
Gázquez Aguilera EM; Rodríguez García M; Cantón Yebra MT
Med Clin (Barc); 2022 May; 158(10):493-494. PubMed ID: 34895746
[No Abstract] [Full Text] [Related]
13. Immunoglobulin A vasculitis post-severe acute respiratory syndrome coronavirus 2 vaccination and review of reported cases.
Hashizume H; Ajima S; Ishikawa Y
J Dermatol; 2022 May; 49(5):560-563. PubMed ID: 35229346
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous leukocytoclastic vasculitis following COVID-19 vaccination with Ad26.COV2.S vaccine: a case report and literature review.
Đorđević Betetto L; Luzar B; Pipan Tkalec Ž; Ponorac S
Acta Dermatovenerol Alp Pannonica Adriat; 2022 Jun; 31(2):83-87. PubMed ID: 35751559
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous leukocytoclastic vasculitis after second dose of mRNA COVID-19 vaccine.
Simon SC; Olsavszky V
Dermatol Online J; 2022 Oct; 28(5):. PubMed ID: 36809133
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 vaccine-induced urticarial vasculitis.
Dash S; Behera B; Sethy M; Mishra J; Garg S
Dermatol Ther; 2021 Sep; 34(5):e15093. PubMed ID: 34369046
[No Abstract] [Full Text] [Related]
17. Cutaneous manifestations of COVID-19 and COVID-19 vaccination.
Nakashima C; Kato M; Otsuka A
J Dermatol; 2023 Mar; 50(3):280-289. PubMed ID: 36636825
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
19. Urticarial vasculitis triggered by SARS-CoV-2 vaccine (mRNA vaccine).
Daldoul M; Korbi M; Bellalah A; Ben Fadhel N; Belhadjali H; Zili J
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):e743-e744. PubMed ID: 35604050
[No Abstract] [Full Text] [Related]
20. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
